Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysis.

Zhang, Peng-Fei; Shi, Xuan-Qiong; Li, Qiu

Zhang, Peng-Fei; Shi, Xuan-Qiong; Li, Qiu.

Afiliación

Zhang PF; Gastric Cancer Center, Division of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Shi XQ; Med-X Center for Informatics, Sichuan University, Chengdu, China.
Li Q; Laboratory of Human Diseases and Immunotherapies, West China Hospital, Sichuan University, Chengdu, China.

Cost Eff Resour Alloc ; 21(1): 65, 2023 Sep 13.

Article en En | MEDLINE | ID: mdl-37705023

Palabras clave

Cost-effectiveness; First-line; Gastric cancer; Markov model; Nivolumab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 1_ASSA2030 Problema de salud: 1_financiamento_saude Tipo de estudio: Health_economic_evaluation Aspecto: Patient_preference Idioma: En Revista: Cost Eff Resour Alloc Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google